Pediatric Acute Otitis Media Clinical Trials: An Analysis of Diversity

Iman S Iqbal1, Elizabeth M Puyo1, Jonathan M Carnino1

  • 1Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts, USA.

Insights

Pediatric acute otitis media (AOM) trials show significant underrepresentation of diverse populations, with most participants being white. This highlights critical gaps in inclusivity for AOM research.

Area of Science:

  • Pediatric clinical research
  • Clinical trial diversity and equity
  • Acute otitis media (AOM) epidemiology

Background:

  • Clinical trials for pediatric acute otitis media (AOM) are crucial for developing effective treatments.
  • Ensuring diverse participant representation in AOM studies is essential for generalizability and equitable healthcare.
  • Existing guidelines for demographic reporting in clinical trials have not fully addressed inclusivity gaps.

Purpose of the Study:

  • To assess the diversity and equity of pediatric acute otitis media (AOM) trials registered on ClinicalTrials.gov.
  • To identify demographic representation gaps in AOM clinical trials.
  • To inform strategies for enhancing inclusivity in future pediatric AOM research.

Main Methods:

  • Retrospective analysis of completed pediatric AOM clinical trials with reported results on ClinicalTrials.gov.
  • Analysis of 48 unique trials focusing on participant demographics (age, sex, race, ethnicity) and trial characteristics (location, sponsor/funder).
  • Evaluation of data completeness regarding race and ethnicity reporting.

Main Results:

  • A significant portion of AOM trials underreported race (43.7%) and ethnicity (25%).
  • The majority of participants in analyzed trials were identified as white (69.9%), indicating disparities in representation.
  • Domestic trials and privately funded trials showed higher rates of demographic reporting compared to international and publicly funded trials, respectively.

Conclusions:

  • Pediatric AOM clinical research urgently requires improved participant diversity and more comprehensive demographic reporting.
  • Despite guidelines, significant gaps in inclusivity persist, necessitating focused efforts.
  • Prioritizing diverse populations in future AOM trials is crucial for ensuring equitable and universally applicable healthcare solutions.
Abstract